Varian develops new probes for nuclear magnetic resonance of solid
6 May 2006
Palo Alto, Calif., USA. Varian, Inc. (NASDAQ:VARI) has developed new
probe technology that is expected to fundamentally improve the ability of
researchers to conduct applications research in solid state NMR (nuclear
magnetic resonance). The FastMAS and UltraFastMAS probes are used to analyze
solid materials meeting diverse application requirements in the life science
and pharmaceutical industries.
The new line of probes is the first commercial product of its kind and is
designed to improve resolution, which increases the value and quality of
spectral data information provided by NMR. Additionally, these probes reduce
the amount of sample required for analysis.
"FastMAS probes open the door for a variety of solid-state NMR
experiments to be conducted that weren't previously possible," said Martin
O'Donoghue, senior vice president of Scientific Instruments, Varian, Inc.
"We expect that method developers will come to see these probes as a
'must-have tool' to provide high performance solid-state results."
Varian has also introduced the BioStatic NMR probe for determining the
molecular structures of proteins and other biomolecules in a solid state.
Bio-solids NMR experiments allow access to 70% of all cellular proteins,
such as membrane proteins, that are considered solids because they are not
free floating in intracellular fluid. These analyses can provide researchers
with unparalleled insight into proteins and biomarker molecules associated
with a wide variety of diseases.
Varian's BioStatic probe incorporates patent pending ultra-low E-field
coil technology to reduce unwanted heating by up to 94% compared to a
standard solenoid coil design probe, and enables experiments to be run up to
5x faster than competitive offerings. Low transfer of heat to the sample is
important to researchers because heating can alter or destroy valuable
biological solids samples.
"Membrane proteins are of considerable interest to our customers because
they represent approximately 65 percent of current drug targets," said
Martin O'Donoghue, senior vice president of Scientific Instruments, Varian,
Inc. "The BioStatic probe is another product in our information rich
detection (IRD) portfolio that demonstrates the continuing innovation of our
NMR research and development team."
Delivery for the new probes is scheduled to begin later this calendar